Status:

WITHDRAWN

Pharmacokinetics of Antiplatelet Drugs in Diabetic pAtients

Lead Sponsor:

Centre hospitalier de l'Université de Montréal (CHUM)

Collaborating Sponsors:

Centre de Recherche du Centre Hospitalier de l'Université de Montréal

Conditions:

Diabetes

Eligibility:

All Genders

18-80 years

Phase:

PHASE4

Brief Summary

Clopidogrel efficacy appears diminished in patients with type 2 diabetes (T2D) who continue to show an increased risk of adverse cardiovascular events and mortality compared to those without T2D.The a...

Detailed Description

Clopidogrel efficacy appears diminished in patients with T2D who continue to show an increased risk of adverse cardiovascular events and mortality compared to those without T2D. To the contrary, respo...

Eligibility Criteria

Inclusion

  • Participants will be ≥18 years old
  • Non-smokers (\>3 months)
  • T2D with good glycemic control A1C\<7.0
  • T2D with poor glycemic control A1C \>7.5
  • Insulin-treated T2D
  • Non-diabetic healthy subjects

Exclusion

  • Subjects with estimated glomerular filtration (MDRD) \<50 mL/min/1.73m2
  • ALT and AST 3 times above the upper limit of normal
  • Organ transplant recipients
  • Inflammatory illnesses (i.e., polyarthritis, hepatitis, cirrhosis, active infectious diseases)
  • Active cancer (except non-melanoma skin cancer)
  • Uncontrolled thyroid functions
  • Inflammatory bowel diseases (ulcerous colitis and Crohn's disease), bariatric surgery
  • Pregnancy
  • History of drug or alcohol abuse
  • Platelet function disorder,
  • One of the following therapies : P2Y12 inhibitors, antithrombotics, antibiotics, anticoagulant, antivirals, CYP450 inducers (carbamazepine, phenobarbital, phenytoin, rifampin, St-John's worth), CYP450 inhibitors (amiodarone, fluoxetine, verapamil), immunosuppressors, INFs, or grapefruit juice (\<4 weeks) or an investigational drug
  • Intolerance or hypersensitivity to antiplatelet drugs or their excipients

Key Trial Info

Start Date :

September 1 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2021

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT02302508

Start Date

September 1 2019

End Date

December 1 2021

Last Update

July 24 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Centre hospitalier de l'Université de Montréal (CHUM)

Montreal, Quebec, Canada, H2X0A9

Pharmacokinetics of Antiplatelet Drugs in Diabetic pAtients | DecenTrialz